Recent studies investigating serum reactivity to the structural proteins of SARS-CoV-2 by flow cytometry have found that approximately 50%–60% of patients with COVID-19 contained antibodies against the SARS-CoV-2 M protein.21 This evidence concerns the gene MYOM2 and COVID-19.